Stocks
Cybin D/B/A Helus PharmaHELP
NASDAQHealthcareBiotechnology$10.19
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing psychedelic-based therapies for mental health conditions, including depression and anxiety disorders. Its lead programs focus on proprietary formulations of psilocybin and deuterated tryptamine compounds, with ongoing clinical trials targeting treatment-resistant depression. Investors track the company for its exposure to the emerging psychedelic therapeutics market and its pipeline progress.
52W Range: $3.76-$15.15
Congressional Interest in Cybin D/B/A Helus Pharma (HELP)
No congressional trades have been disclosed for Cybin D/B/A Helus Pharma (HELP) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading HELP?
No congressional trades found for this stock.